Kornimate/medical-research-clean huggingface dataset:
cervical erector spinae block versus interscalene block for shoulder surgery

Conditions: Pain, Acute; Opioid Use

Summary: severe pain after arthroscopic surgery is a common experience for the patients . different regional anesthetic technique has been applicated for postoperative pain relief . the main goal of regional anesthesia regarding postoperative pain relief is to reduce opioid requirements. the most commonly used approach is interscalene brachial plexus block (isb), since it provides effective postoperative analgesia upto 12 hours. erector spinae plane block (espb) has been reported for a variety of indications such as thoracic and abdominal surgery. recently, a novel description of a t2-3 erector spinae plane (esp) as an alternative to a bp block for an upper extremity surgical procedure. following these studies, direct cervical esp block has been recently performed successfully as both clinical and cadaveric study. the investigators hypothesized that cervical esp block is as effective as (non-inferior) interscalene brachial plexus block in terms of postoperative analgesia of shoulder surgery. to evaluate the effectiveness of the cervical esp block, the investigators have designed a randomized study. primary aim is to evaluate the postoperative opioid consumption. secondary aim is to evaluate postoperative pain scores by numeric rating scale (0 to 10 point scale).

this study has been designed as a prospective, randomized and single-blind trial. local ethics committee of ataturk university has approved the study (b.30.2.ata.0.01.00/142). after obtaining the patients' written informed consents, we will include a total number of 94 patients (47 patients for each group). the inclusion criteria of the study was considered as age between 18-80, american society of anesthesiologists (asa) status i-iii, eligible for regional anesthesia, and unilateral shoulder surgery. the patients who have clotting disorder, contra-indication for regional anesthesia, infection on the injection site, chronic opioid usage, previous same side shoulder surgery, severe chronic obstructive pulmonary disease (copd) , diaphragmatic paralysis, bmi 35 or over will be excluded. a computer-generated randomization program will be used to allocate the patient into two groups. interscalene brachial plexus block group will be named as group isb (n=47) and cervical esp block group will be named as group cesp (n=47). the assessor of the outcomes will be blinded to the study groups of the patients. both isb block and cervical esp block will be performed under ultrasound guidance in the block room preoperatively.

Eligibility criteria:
inclusion criteria: 1. age between 18-80 2. asa i-iii 3. eligible for regional anesthesia 4. unilateral shoulder surgery exclusion criteria: 1. the patients who have clotting disorder 2. contra-endication for regional anesthesia 3. infection on the injection site 4. chronic opioid usage 5. previous same side shoulder surgery 6. severe copd 7. diaphragmatic paralysis 8. bmi 35 or over
descartes-15 for patients with relapsed/refractory multiple myeloma

Conditions: Refractory Multiple Myeloma; Relapsed Multiple Myeloma

Summary: this is a phase i dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous bcma-targeting rna-engineered car t-cell therapy in patients with relapsed/refractory multiple myeloma. the cell product is referred to as descartes-15


Eligibility criteria:
inclusion criteria * patients must be 18 years of age or older at the time of enrollment. * patients must be diagnosed with active and measurable relapsed/refractory multiple myeloma. * patients must have failed at least 3 prior lines of therapy which must have included an immunomodulatory drug, a proteasome inhibitor, and an anti-cd38 drug or biologic. failure of treatment and measurable myeloma disease are defined as per 2016 imwg criteria. * patients must have clinical performance status of ecog 0-2. * patients must have adequate vital organ function as defined by: * hemoglobin ≥8 g/dl * absolute neutrophil count \> 1000/ mm3 * platelets \> 50,000/mm3 * alt/ast levels lower than 3-fold of normal * creatinine clearance ≥45 ml/min/1.73 m2 * normal cardiac and pulmonary function * no thromboembolic events in the past 3 months * no heparin allergy or active infection exclusion criteria * patients who have any active and uncontrolled infection. * ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above 40 mg/day prednisone equivalent). * patients who have active central nervous system disease.

Keywords: relapsed/refractory relapsed myeloma refractory myeloma multiple myeloma car-t cart descartes-15 descartes myeloma t cells cell gene
promoting physical growth and positive development in severely stunted guatemalan children

Conditions: Malnutrition; Developmental Disabilities

Summary: this study seeks to evaluate the impact of an intensive home-based education intervention targeting severely stunted guatemalan children for catch up growth and improved development. half of the children in the study will receive standard of care, which includes micronutrient supplementation and a food ration. the other half of children in the study will receive, in addition to the above, home-based dietary assessment and individualized parental nutrition education.


Eligibility criteria:
inclusion criteria: * child aged 6-24 months at time of enrollment * height/length for age z score of less than -2.5 * child lives with parent/legal guardian exclusion criteria: * presence of acute malnutrition (weight for length/height z score of less than -2) * presence of other severe medical illness (e.g. congenital heart disease, genetic abnormality)
evaluating the efficacy of temperature-controlled radiofrequency (trf) in the treatment of vulvovaginal atrophy.

Conditions: Postmenopausal Vulvovaginal Atrophy

Summary: this project will be a prospective, multicenter, randomized cohort study. the investigators will select patients with vulvovaginal atrophy who have indications for treatment, and set up the experimental group (peninsula temperature-controlled radiofrequency therapeutic apparatus group) and the control group (promestriene vaginal soft capsules group). changes in vaginal exfoliated cell maturity index (mv), score of vaginal symptoms and signs, vaginal health index score (vhis), female sexual function index score (fsfi), visual analogue score (vas) before and after treatment, and adverse effects will be observed to analyze the safety and efficacy of temperature-controlled radiofrequency therapy for vulvovaginal atrophy in postmenopausal women.


Eligibility criteria:
inclusion criteria: * menopausal time at least one year. * genitourinary syndrome of menopause (gsm) related symptoms with moderate or severe intensity, such as dryness and dyspareunia, etc. * blood fsh≥30 iu/l (30miu/ml)。 * clinical symptoms and signs of vaginal atrophy score≥15. * breast ultrasound examination was grade 1-3 within 9 months before the study. * voluntary participation in clinical trials and signed informed consent. * patients followed the treatment regimen and completed the study. exclusion criteria (one of the following criteria is excluded) : * the patients who did not meet the inclusion criteria * received estrogen replacement therapy (including local and systemic medication) within 3 months. * received any medicine (such as baofukang suppository) to treat vulvovaginal atrophy within 3 months. * corticosteroids were used within 6 weeks. long-term corticosteroids were used (intermittent nasal or skin application, eye drops and ears are allowed). * other experimental drugs were used within 1 month. * received vaginal laser therapy within 6 months. * patients with acute urinary tract infection; * patients with acute genital tract infection (genital herpes, trichomonad, fungal vaginitis; gonococcus, mycoplasma, chlamydia infection and bacterial vaginosis, etc.); * patients with pelvic organ prolapse greater than or equal to stage ii; * patients with metal intrauterine device (iud)； * patients with precancerous lesions or malignant tumors of vagina and cervix; * patients with serious heart, liver, brain, kidney, endocrine diseases, etc. * allergic to control drug and excipients. * other malignancies are known or suspected. * with estrogen-dependent neoplasm. * confirm a history of depression or serious mental illness. * there were consciousness barriers and communication barriers that could not cooperate with the experiment. * patients considered unsuitable for this clinical trial.

Keywords: vulvovaginal atrophy temperature-controlled radiofrequency postmenopausal woman genitourinary syndrome of menopause
personalized lifestyle program in treatment resistant irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: patients with treatment resistant irritable bowel syndrome (ibs) are recruited from secondary care gastroenterology clinics in stockholm and screened for eligibility criteria. participants follow a 12 month treatment program at nordic clinic, a clinic offering personalized lifestyle interventions based on the functional medicine model. in parallel with the treatment program, the participant are clinically assessed for the evaluation of the treatment after 6 months, 12 months, 18 months and 24 months

patients with treatment resistant irritable bowel syndrome (ibs) are recruited from secondary care gastroenterology clinics in stockholm. eligible participants are screened for eligibility criteria at a baseline visit at the karolinska institutet. patients providing written informed consent for participation are invited to nordic clinic, a clinic offering personalized lifestyle interventions based on the functional medicine model. before the first visit to the clinic, the participant fill out a longer questionnaire that is used for the planning of the participant's personal treatment program. at the first visit, the therapist goes through the responses together with the participant. based on the participant's symptom profile, it is determined which tests are taken in the first step. based on symptoms and test results, the therapist and participant come up with a treatment plan that can include several of the following components: * dietary changes * dietary supplements * measures to improve sleep / circadian rhythm * stress management * physical exercise * medicines, in exceptional cases. the treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. the treatment involves a total of 9 visits to the nordic clinic during one year. the subsequent visits are planned by the therapist at the nordic clinic together with the participant. in parallel with the treatment program, the participant makes return visits to karolinska institutet to collect follow-up data for the evaluation of the treatment after 6 months, 12 months, 18 months and 24 months after the start of treatment where participants are clinically assessed and fill out forms for the evaluation of treatment.

Eligibility criteria:
inclusion criteria: * fulfills rome iv criteria for ibs * symptom burden on ibs-sss \>175 * no symptom relief from standard medical treatment * no organic finding explaining the ibs symptoms (e.g. inflammation, parasites, thyroid disease, lactose intolerance, celiac disease, bile acid malabsorption) exclusion criteria: * pregnancy * disease or life circumstances that prevent participation in the treatment program
continuous versus 1-min oscillometric arterial bp monitoring

Conditions: Anesthesia, General

Summary: hypotension is common during surgery and about one-third of hypotension occur during the period from anesthesia induction to skin incision. therefore, monitoring blood pressure during this period is crucial. two methods are used for measuring blood pressure during surgery: the intermittent measurement method (oscillometric method) and the continuous measurement method (arterial catheterization method). the latter is frequently used in surgical patients who require meticulous hemodynamic management, although there is no clearly defined indication for its use. despite the benefits of arterial catheterization, it is often delayed after induction of general anesthesia, and blood pressure is monitored intermittently using the oscillometric method. a recent study showed that continuous arterial pressure monitoring using arterial catheterization method during the induction of general anesthesia reduced hypotension significantly compared to 2.5-min interval intermittent arterial pressure monitoring using oscillometric method. the study was conducted on patients scheduled for continuous arterial pressure monitoring during surgery and the group with continuous arterial pressure monitoring showed significantly lower incidence of hypotension during the first 15 minutes of anesthesia induction. however, measuring blood pressure using the oscillometric method at 1-min interval, rather than 2.5-min interval, may not be significantly inferior to continuous monitoring via arterial catheterization in terms of hypotension occurrence. this study aims to compare hypotension incidence between arterial catheterization method and oscillometric method with 1-min interval during induction of anesthesia in non-cardiac surgery patients.


Eligibility criteria:
inclusion criteria: * adult patients aged 19 or older undergoing scheduled non-cardiac surgery with general anesthesia and continuous invasive arterial blood pressure monitoring via the radial artery exclusion criteria: * arterial access is clinically necessary before induction of anesthesia (e.g., moderate or higher degree of aortic stenosis, moderate or higher degree of heart failure, coronary artery disease requiring revascularization, intracranial aneurysm with a significant risk of rupture, etc.) * emergency surgery * american society of anesthesiologists (asa) physical status 5 or 6 * arterial access is required in a different artery other than the radial artery (e.g., the femoral artery) * electrocardiogram other than sinus rhythm * refusal to participate in the study

Keywords: intraoperative hypotention induction of anesthesia arterial blood pressure monitoring
esthesioneuroblastoma: outcomes after treatment

Conditions: Esthesioneuroblastoma, Olfactory

Summary: the purpose of this study is to collect and organize data into a repository to gather relevant information for future research from patients diagnosed with a rare malignant sinonasal cancer called esthesioneuroblastoma (enb) and are scheduled to undergo endonasal skull base surgery. data being collected includes surgical data, demographics, disease presentation, mri, ct, pet imaging, and post-operative assessments including pathology tests. after surgery, the investigators will collect chemotherapy and radiation data. participants will also complete quality of life questionnaires at their follow-up visits.


Eligibility criteria:
inclusion criteria: * between the age of 10-80 years * diagnosed with esthesioneuroblastoma exclusion criteria: * refusal to participate

Keywords: esthesioneuroblastoma tumor skull base surgery sinonasal cancer
transcranial alternating current stimulation (tacs) for auditory hallucinations

Conditions: Schizophrenia

Summary: transcranial alternating current stimulation (tacs) can modulate and restore neural oscillations that are reduced in patients with psychiatric illnesses such as schizophrenia. here, we performed a open-lable study of clinical trial in 30 schizophrenia patients with auditory hallucinations to show that tacs is effective for auditory hallucinations.

each week, the patient rested quietly with her eyes open while receiving alpha-frequency tacs for 40 minutes. stimulation was delivered at 10 hz with 1 ma zero-to-peak amplitude in-phase to the location 1 and the location 2 acquired by the meg technique with 5\*5 cm electrodes. a 5\* 7 cm return electrode was centered on cz. in total, 20 weeks.

Eligibility criteria:
inclusion criteria: * schizophrenia with auditory hallucinations was diagnosed by dsm-iv, ahrs \>12, take sufficient antipsychotics for at least 1 month. exclusion criteria: * current pregnancy, major medical illness affecting the central nervous system, significant neurologic disorders, intake of drugs including supplements like essential fatty acids that influence prostaglandins or niacin skin flush flash pathway metabolism, a history of suicide risk, or alcohol or drug abuse.
the effect of dietary nitrates on physical performance and vascular function in chronic kidney disease

Conditions: Kidney Disease, Chronic; Endothelial Dysfunction

Summary: the purpose of this study is to examine the effect of acute ingestion of a concentrated beetroot juice supplement on vascular function and exercise capacity in patients with moderate to severe chronic kidney disease

people with chronic kidney disease (ckd) are at an increased risk of cardiovascular disease. blood vessel dysfunction and exercise intolerance are common in ckd. blood vessel dysfunction has been shown to predict future cardiovascular events and decreased physical activity can contribute to an increased risk of cardiovascular disease. therefore, this study investigates if dietary nitrate from beetroot juice, which has been shown to improve blood vessel function and exercise capacity in other cardiovascular disease pathologies, could be effective at improving these measures in patients with ckd. in a controlled, double blinded trial, stage 3-5 ckd patients will be randomly assigned to receive either beetroot beverage or a placebo and then complete measures of blood vessel function and an exercise test.

Eligibility criteria:
inclusion criteria: • stage 3-5 chronic kidney disease exclusion criteria: * history of cardiovascular disease * current pregnancy * uncontrolled hypertension * uncontrolled hyperlipidemia * current hormone replacement therapy * current use of tobacco products * current autoimmune disease * current hyperkalemia * diagnosis of a deep vein thrombosis (dvt) within the last 6 months

Keywords: chronic kidney disease dietary nitrates beetroot juice endothelium, vascular cardiovascular disease exercise capacity
comparative study of inclined treadmill and dynamic cycling on balace in hearing impaired children.

Conditions: Balance Assessment

Summary: hearing loss is generally identified initially in life leading to difficulties in communication. in children, vestibular dysfunctions can cause a deficit in gross motor development and balance stability. at an early age, delayed gross motor development can cause impairment in the bilateral vestibular system and sensorineural hearing. the children with balance impairment cannot usually participate in physical activities. running, cycling, hoping and leading to social isolation3. in pakistan, 2.49% of the population suffers from some disability; the hearing loss population is 7.4%. in pakistan, hearing loss is more reported in males as compared to females. according to the non-official data, nearly 1.2 in every 1000 pakistani children suffer from moderate to severe bilateral hearing loss5. in this, 15% population is suffering from profound and nearly 85% from moderate to severe hearing loss.children who have vestibular dysfunctions may experience many disorders of the vestibular system.acute unilateral vestibular loss (auvl) is the most frequent vestibular dysfunction. the etiology of acute unilateral vestibular loss is unknown, but the studies say it may be due to genetic and acquired causes (inflammatory and viral infections). the symptoms include static

this study seeks to provide a detailed understanding of the effects of dynamic cycling and inclined treadmill training on the motor skills of children with hearing impairments through an extensive review of relevant literature, careful data collection, and robust statistical analysis. the findings may assist parents, educators, and healthcare professionals in making informed choices about the most effective therapies to enhance mobility and overall development in children with hearing impairments. ultimately, this research contributes to pediatric rehabilitation and promotes a holistic approach to addressing the specific needs of children with hearing loss.

Eligibility criteria:
inclusion criteria: children of age 8 to 10 years consistency in hearing impairment ability to understand the command exclusion criteria: children with any acute or chronic disease recurrent falls history of any msk disease -

Keywords: balance dynamic cycling gait
open-label extension to the phase 2 crossover study (presidio) evaluating kzr-616 in patients with pm and dm.

Conditions: Polymyositis; Dermatomyositis

Summary: this was an open-label study to evaluate the long-term efficacy and safety of kzr-616 in patients with active polymyositis (pm) or dermatomyositis (dm) who completed the double-blind treatment period of study kzr-616-003, up to and including the week 32 visit, prior to the first dose of open-label kzr-616.

this was an open-label study to evaluate the long-term efficacy and safety of kzr-616 in patients with active polymyositis or dermatomyositis who completed the double-blind treatment period of study kzr-616-003 (nct04033926), up to and including the week 32 visit, prior to the first dose of open-label kzr-616. patients were evaluated for eligibility according to the entry criteria at, or within 8 weeks after, the week 32 visit (ie, the end of treatment \[eot\] visit \[visit 34\]) of study kzr-616-003. all patients received a subcutaneous (sc) injection of 30 mg kzr-616 at visit 1 (day 1), followed by weekly sc injections of 45 mg kzr-616 up to a maximum of 96 weeks. study drug administration ended for all patients in study kzr-616-003e when the last patient enrolled completed 48 weeks of dosing. patients had a final follow-up visit 12 weeks after their last dose of kzr-616 (end of study \[eos\] visit), for a maximum potential length of participation of 108 weeks.

Eligibility criteria:
inclusion criteria: * must have successfully completed study kzr-616-003 through week 32, including the week 32 visit assessments * women of childbearing potential (wocbp) must have a negative urine or serum pregnancy test prior to the first dose of kzr-616 in kzr-616-003e, and must agree to continue to use a highly effective method of birth control until completion of the study. * male patients must continue to use an effective contraception method for 1 week following their last dose of kzr-616 or be congenitally or surgically sterile. exclusion criteria: * has participated in any clinical study other than kzr-616-003 between the week 32 visit of study kzr-616-003 and the first study visit of kzr-616-003e, if they are not on the same calendar day. * are females who are breastfeeding or who plan to become pregnant during the study, or who are actively trying to conceive at the time of signing of the informed consent form. * have hypersensitivity to kzr-616 or any of its excipients.

Keywords: myositis idiopathic inflammatory myopathies polymyositis dermatomyositis musculoskeletal diseases muscular diseases